SEC Form 4 · accession 0001213900-18-009128
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nadav Kidron
Officer — President and CEO · Director · 10% Owner
Period of report
Jul 10, 2018
Accepted (ET)
Jul 12, 2018 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 10, 2018 | S | 61 | $5.9831 | D | 958,087 | D | |
| Common StockF1 | Jul 11, 2018 | P | 122 | $5.9195 | A | 958,209 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On July 12, 2018, Mr. Kidron paid to Oramed Pharmaceuticals Inc. $3.88, representing the full amount of the profit realized in connection with these short-swing transactions.